Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment
Source abstract
Abstract
Breast cancer (BC) remains a leading cause of morbidity and mortality among women worldwide, with triple-negative breast cancer (TNBC) posing significant treatment challenges due to its aggressive phenotype and resistance to conventional therapies. Recent advancements in nanocarrier technology offer promising solutions for enhancing drug delivery, improving bioavailability, and increasing drug accumulation at tumor sites through targeted approaches. This review delves into the latest innovations in BC detection and treatment, highlighting the role of nanocarriers like polymeric micelles, liposomes, and magnetic nanoparticles in overcoming the limitations of traditional therapies. Additionally, the manuscript discusses the integration of cutting-edge diagnostic tools, such as multiplex PCR-Nested Next-Generation Sequencing (mPCR-NGS) and blood-based biomarkers, which are revolutionizing early detection and molecular profiling of BC. The convergence of these technologies not only enhances therapeutic outcomes but also paves the way for personalized medicine in BC management. This comprehensive review underscores the potential of nanocarriers in transforming BC treatment and emphasizes the critical importance of early detection in improving patient prognosis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Harbeck N, et al. Breast cancer. Nat Rev Disease Primers. 2019;5(1):66.10.1038/s41572-019-0111-2 ↗
2. Akram M, et al. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.10.1186/s40659-017-0140-9 ↗
3. Sharma GN, et al. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109–26.10.4103/2231-4040.72251 ↗
4. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.10.1001/jama.2018.19323 ↗
5. Singh SK, et al. Drug delivery approaches for breast cancer. Int J Nanomed. 2017;12:6205–18. https://doi.org/10.2147/IJN.S140325.10.2147/IJN.S140325 ↗
6. Malliappan SP, et al. Breast cancer targeted treatment strategies: Promising nanocarrier approaches. Anti-cancer Agents Med Chem. 2020;20(11):1300–10.10.2174/1871520619666191022175003 ↗
7. Khan I, et al. Polymeric nanocarriers: A new horizon for the effective management of breast cancer. Curr Pharm Design. 2017;23(35):5315–26.
8. Olov N, et al. Combinational drug delivery using nanocarriers for breast cancer treatments: a review. J Biomed Mater Res Part A. 2018;106(8):2272–83.10.1002/jbm.a.36410 ↗
9. Naz S, et al. Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment. Artificial Cells Nanomed Biotechnol. 2018;46(5):899–916.10.1080/21691401.2017.1375937 ↗
10. Algebaly AS, et al. Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer. Clin Transl Oncol. 2021;23(1):74–81.10.1007/s12094-020-02385-9 ↗
11. Filippini SE, Vega A. Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci. 2013;18(4):1358–72.10.2741/4185 ↗
12. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56(1):37–47.10.3322/canjclin.56.1.37 ↗
13. Penault-Llorca F. Commentaires sur la nouvelle classification TNM/AJCC des cancers du sein: quoi de neuf pour le pathologiste?” [Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What’s new for the pathologist?]. Annales Pathologie. 2003;23(6):492–5.
14. Fangyan Yu, Leong KW, Makrigiorgos A, Adalsteinsson VA, Ladas I, Ng K, Harvey Mamon G, Makrigiorgos M. NGS-based identification and tracing of microsatellite instability from minute amounts DNA using inter-Alu-PCR. Nucleic Acids Res. 2021;49(4):26.
15. Jones S, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):28353.10.1126/scitranslmed.aaa7161 ↗
16. Merino Bonilla JA et al. (2017) Breast cancer in the 21st century: from early detection to new therapies.” “El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos. Radiologia 59(5): 368–37910.1016/j.rx.2017.06.003 ↗
17. Tagliafico AS, et al. Overview of radiomics in breast cancer diagnosis and prognostication. Breast. 2020;49:74–80.10.1016/j.breast.2019.10.018 ↗
18. Tarighati E, et al. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med. 2023;23(1):1–16.
19. Kamali H, et al. The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors. J Nanobiotechnol. 2022;20(1):438.10.1186/s12951-022-01640-1 ↗
20. Moss J, et al. Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer. Annals Oncol. 2020;31(3):395–403.10.1016/j.annonc.2019.11.014 ↗
21. Grady S, Morgan MP. Microcalcifications in breast cancer: from pathophysiology to diagnosis and prognosis. Biochim Biophys Acta Rev Cancer. 2018;1869(2):310–20.10.1016/j.bbcan.2018.04.006 ↗
22. Miao Y, Tang S. Detection of breast cancer lump and BRCA1/2 genetic mutation under deep learning. Comput Intell Neurosci. 2022;2022:9591781.10.1155/2022/9591781 ↗
23. Jotwani AC, Gralow JR. Early detection of breast cancer: new biomarker tests on the horizon? Mol Diagn Ther. 2012;13(6):349–57.10.1007/BF03256340 ↗
24. Barton S, Swanton C. Recent developments in treatment stratification for metastatic breast cancer. Drugs. 2011;71(16):2099–113.10.2165/11594480-000000000-00000 ↗
25. Chen R, et al. Improved anti-triple negative breast cancer effects of docetaxel by RGD-modified lipid-core micelles. Int J Nanomed. 2021;16:5265–79.10.2147/IJN.S313166 ↗
26. Elliott MJ, et al. Current treatment and future trends of immunotherapy in breast cancer. Curr Cancer Drug Targets. 2022;22(8):667–77.10.2174/1568009622666220317091723 ↗
27. Tan TJ, et al. What is the role of immunotherapy in breast cancer? Chin Clin Oncol. 2018;7(2):13.10.21037/cco.2018.04.01 ↗
28. Mu Q, Wang H, Zhang M. Nanoparticles for imaging and treatment of metastatic breast cancer. Expert Opin Drug Deliv. 2017;14(1):123–36. https://doi.org/10.1080/17425247.2016.1208650. (Epub 2016 Jul 19).10.1080/17425247.2016.1208650 ↗
29. Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3–23.10.2174/2211738507666190122111224 ↗
30. Garrido-Castro AC, et al. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.10.1158/2159-8290.CD-18-1177 ↗
31. Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–17.10.1007/s00262-020-02736-z ↗
32. Liao M, et al. Small-molecule drug discovery in triple negative breast cancer: current situation and future directions. J Med Chem. 2021;64(5):2382–418.10.1021/acs.jmedchem.0c01180 ↗
33. Fosu-Mensah N, et al. Advances in small-molecule drug discovery for triple-negative breast cancer. Fut Med Chem. 2015;7(15):2019–39.10.4155/fmc.15.129 ↗
34. Islam R, Lam KW. Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. Eur J Med Chem. 2020;207:112812.10.1016/j.ejmech.2020.112812 ↗
35. Jia H, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updates. 2017;32:1–15.10.1016/j.drup.2017.07.002 ↗
36. Das A, et al. Repurposing drugs as novel triple-negative breast cancer therapeutics. Anti-Cancer Agents Med Chem. 2022;22(3):515–50.10.2174/1871520621666211021143255 ↗
37. Alven S, Atim Aderibigbe B. The therapeutic efficacy of dendrimer and micelle formulations for breast cancer treatment. Pharmaceutics. 2020;12(12):1212.10.3390/pharmaceutics12121212 ↗
38. Svenson S, Tomalia DA. Dendrimers in biomedical applications–reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106–29.10.1016/j.addr.2005.09.018 ↗
39. Abedi-Gaballu F, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018;12:177–90.10.1016/j.apmt.2018.05.002 ↗
40. Sethi P, et al. 3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation. Nanomed Nanotechnol Biol Med. 2015;11(8):2013–23.10.1016/j.nano.2015.07.013 ↗
41. Upreti M, et al. Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. Oncotarget. 2016;7(27):41559–74.10.18632/oncotarget.9490 ↗
42. Buhleier E, Wehner W, Vögtle F. “Cascade”-and" nonskid-chain-like" syntheses of molecular cavity topologies. Synthesis. 1978;1978(02):155–8.10.1055/s-1978-24702 ↗
43. Salimi M, et al. Treatment of breast cancer-bearing BALB/c mice with magnetic hyperthermia using dendrimer functionalized iron-oxide nanoparticles. Nanomaterials. 2020;10(11):2310.10.3390/nano10112310 ↗
44. Liu Z, Liu Y, Liu Z. Recent advances in the growth mechanisms of single-walled carbon nanotubes and multi-walled carbon nanotubes. Front Nanotechnol. 2021;3:648297.
45. Kesharwani P, Iyer AK, Ljubimova JY. Dendrimer-based nanocarriers for drug delivery. Small. 2015;11(42):5086–106.
46. Chauhan AS, et al. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromol. 2019;10(5):1195–202.10.1021/bm9000298 ↗
47. Han B, et al. Elemene nanoemulsion inhibits metastasis of breast cancer by ROS scavenging. Int J Nanomed. 2021;16:6035–48.10.2147/IJN.S327094 ↗
48. Miranda M, Eustáquio S, et al. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomed Pharmacother. 2021;133:110936.10.1016/j.biopha.2020.110936 ↗
49. Song B, et al. Folate modified long circulating nano-emulsion as a promising approach for improving the efficiency of chemotherapy drugs in cancer treatment. Pharm Res. 2020;37(12):242.10.1007/s11095-020-02811-1 ↗
50. Dartora VFC, et al. Hyaluronic acid nanoemulsions improve piplartine cytotoxicity in 2D and 3D breast cancer models and reduce tumor development after intraductal administration. Int J Biol Macromol. 2022;219:84–95.10.1016/j.ijbiomac.2022.07.162 ↗
51. Su DS, Centi G. A perspective on carbon materials for future energy application. J Energy Chem. 2013;22(2):151–73.10.1016/S2095-4956(13)60022-4 ↗
52. Yuan Z, Luan F, Li Y. Recent advances in food-grade nanoemulsions and their potential applications in food preservation and bioactive delivery. Food Biosci. 2021;41:100973.10.1016/j.fbio.2021.101034 ↗
53. Zhang R, Li H, Hou T, Li B. Recent advances in food-grade nanoemulsions: fabrication, structure, and functionality. Food Hydrocolloids. 2020;105:105790.10.1016/j.foodhyd.2020.105790 ↗
54. Badea MA, Balas M, Prodana M, Cojocaru FG, Ionita D, Dinischiotu A. Carboxyl-functionalized carbon nanotubes loaded with cisplatin promote the inhibition of PI3K/Akt pathway and suppress the migration of breast cancer cells. Pharmaceutics. 2022;14(2):469.10.3390/pharmaceutics14020469 ↗
55. Tajabadi M. Application of carbon nanotubes in breast cancer therapy. Drug Res. 2019. https://doi.org/10.1055/a-0945-1469.10.1055/a-0945-1469 ↗
56. Saha LC, et al. An immunologically modified nanosystem based on noncovalent binding between single-walled carbon nanotubes and glycated chitosan. Technol Cancer Res Treat. 2018;17:153303381880231.10.1177/1533033818802313 ↗
57. Karnati KR, Wang Y. Understanding the co-loading and releasing of doxorubicin and paclitaxel using chitosan functionalized single-walled carbon nanotubes by molecular dynamics simulations. Phys Chem Chem Phys. 2018;20(14):9389–400.10.1039/C8CP00124C ↗
58. Dahri M, et al. Loading and release of cancer chemotherapy drugs utilizing simultaneous temperature and pH-responsive nanohybrid. BMC Pharmacol Toxicol. 2021;22(1):41.10.1186/s40360-021-00508-8 ↗
59. Thakur CK, et al. Lysinated multiwalled carbon nanotubes with carbohydrate ligands as an effective nanocarrier for targeted doxorubicin delivery to breast cancer cells. Molecules. 2022;27(21):7461.10.3390/molecules27217461 ↗
60. Chauhan AS, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Controll Rel. 2003;90(3):335–43.10.1016/S0168-3659(03)00200-1 ↗
61. Kostarelos K, et al. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol. 2009;4(10):627–33.10.1038/nnano.2009.241 ↗
62. Yang L, Ren Y, Cui C, Jia B, Zhao C, Jiang Z, et al. Carbon nanotubes in combination with photothermal therapy to treat hepatocellular carcinoma. BMC Gastroenterol. 2021;21(1):1–9.10.1186/s12876-020-01553-z ↗
63. Ye Z, et al. EGFR targeted cetuximab-valine-citrulline (VC)-doxorubicin immunoconjugates- loaded bovine serum albumin (BSA) nanoparticles for colorectal tumor therapy. Int J Nanomed. 2021;16:2443–59.10.2147/IJN.S289228 ↗
64. Yang Z, et al. Engineered bovine serum albumin-based nanoparticles with pH-sensitivity for doxorubicin delivery and controlled release. Drug Deliv. 2020;27(1):1156–64.10.1080/10717544.2020.1797243 ↗
65. Haque ST, et al. Fe/Mg-modified carbonate apatite with uniform particle size and unique transport protein-related protein corona efficiently delivers doxorubicin into breast cancer cells. Nanomaterials. 2020;10(5):834.10.3390/nano10050834 ↗
66. Tan T, et al. Chondroitin sulfate-mediated albumin corona nanoparticles for the treatment of breast cancer. Asian J Pharm Sci. 2021;16(4):508–18.10.1016/j.ajps.2021.03.004 ↗
67. Marshall SK, et al. Biomimetic targeted theranostic nanoparticles for breast cancer treatment. Molecules. 2022;27(19):6473.10.3390/molecules27196473 ↗
68. Wu X, et al. Long intergenic non-protein coding RNA 1094 (LINC01094) promotes the progression of breast cancer (BC) by regulating the microRNA-340–5p (miR-340–5p)/E2F transcription factor 3 (E2F3) axis. Bioengineered. 2021;12(1):9046–57.10.1080/21655979.2021.1993715 ↗
69. Wang Z, et al. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN. BMC Cancer. 2021;21(1):1188.10.1186/s12885-021-08914-1 ↗
70. Zhang H, et al. MiR-135a-5p suppresses breast cancer cell proliferation, migration, and invasion by regulating BAG3. Clinics. 2022;77:100115.10.1016/j.clinsp.2022.100115 ↗
71. Askar MA, et al. Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: in vitro and in vivo studies. Tumour Biol. 2021;43(1):225–47.10.3233/TUB-211506 ↗
72. Guo W, et al. Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy. Sci Rep. 2020;10(1):7832.10.1038/s41598-020-64828-1 ↗
73. Ashkbar A, et al. Treatment of breast cancer in vivo by dual photodynamic and photothermal approaches with the aid of curcumin photosensitizer and magnetic nanoparticles. Sci Rep. 2020;10(1):21206.10.1038/s41598-020-78241-1 ↗
74. Khan R. Functionalized nanomaterials targeting NLRP3 inflammasomes driven immunomodulation: friend or foe. Nanoscale. 2023;15(39):15906–28.10.1039/D3NR03857B ↗
75. Prakash R, et al. NLRP3 inflammasome-targeting nanomicelles for preventing ischemia-reperfusion-induced inflammatory injury. ACS Nano. 2023;17(9):8680–93.10.1021/acsnano.3c01760 ↗
76. Rao L, et al. Activating macrophage-mediated cancer immunotherapy by genetically edited nanoparticles. Adv Mater. 2020;32(47):e2004853.10.1002/adma.202004853 ↗
77. Ahmed M, Douek M. The role of magnetic nanoparticles in the localization and treatment of breast cancer. BioMed Res Int. 2013;2013:281230.10.1155/2013/281230 ↗
78. Zhang H, et al. Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression. Proc Natl Acad Sci USA. 2019;116(16):7744–9.10.1073/pnas.1817251116 ↗
79. de Kruijff RM, et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9(1):11671.10.1038/s41598-019-48298-8 ↗
80. Hullo M, et al. Radiation enhancer effect of platinum nanoparticles in breast cancer cell lines: in vitro and in silico analyses. Int J Mol Sci. 2021;22(9):4436.10.3390/ijms22094436 ↗
81. Guo Y, Yan Z, Tang H, Zhang D, Dong Y, Liu S, et al. Nanoparticle-based photothermal therapy for breast cancer noninvasive treatment. J Nanoparticle Res. 2020;23(3):1–12.
82. Estelrich J, et al. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomed. 2015;10:1727–41.
83. Rokade SS, et al. Gloriosa superba mediated synthesis of platinum and palladium nanoparticles for induction of apoptosis in breast cancer. Bioinorg Chem Appl. 2018;2018:4924186.10.1155/2018/4924186 ↗
84. Mehrnia SS, et al. Radiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles. Radiat Oncol. 2021;16(1):33.10.1186/s13014-021-01751-3 ↗
85. Cui L, et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nat Biotechnol. 2021;39(3):357–67.10.1038/s41587-020-0707-9 ↗
86. Rakowski M, et al. Silver nanoparticles modulate the epithelial-to-mesenchymal transition in estrogen-dependent breast cancer cells in vitro. Int J Mol Sci. 2021;22(17):9203.10.3390/ijms22179203 ↗
87. Medina MA, et al. Synthesis, characterization and magnetic hyperthermia of monodispersed cobalt ferrite nanoparticles for cancer therapeutics. Molecules. 2020;25(19):4428.10.3390/molecules25194428 ↗
88. Ahamed M, et al. SnO2-doped ZnO/reduced graphene oxide nanocomposites: synthesis, characterization, and improved anticancer activity via oxidative stress pathway. Int J Nanomed. 2021;16:89–104.10.2147/IJN.S285392 ↗
89. Ahamed M, et al. Biosynthesis, characterization, and augmented anticancer activity of ZrO2 doped ZnO/rGO nanocomposite. J Funct Biomater. 2023;14(1):38.10.3390/jfb14010038 ↗
90. Bayón-Cordero L, et al. Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials. 2019;9(3):474.10.3390/nano9030474 ↗
91. Joun I, et al. Advances in lipid-based nanocarriers for breast cancer metastasis treatment. Front Med Technol. 2022;4:893056.10.3389/fmedt.2022.893056 ↗
92. Chaudhuri A, et al. Lipid-based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy. Int J Mol Sci. 2022;23(17):10068.10.3390/ijms231710068 ↗
93. Fernandes RS, et al. In vitro and in vivo effect of pH-sensitive PLGA-TPGS-based hybrid nanoparticles loaded with doxorubicin for breast cancer therapy. Pharmaceutics. 2022;14(11):2394.10.3390/pharmaceutics14112394 ↗
94. Benizri S, et al. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res Lett. 2018;13:1–17.10.1186/s11671-017-2420-2 ↗
95. Ji P, Yu T, Liu Y, Jiang J, Xu J, Zhao Y, Hao Y, Qiu Y, Zhao W, Wu C. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Design Dev Ther. 2016;10:911–25.
96. Tang L, et al. TPGS2000-DOX prodrug micelles for improving breast cancer therapy. Int J Nanomed. 2021;16:7875–90.10.2147/IJN.S335405 ↗
97. Gregoriou Y, et al. Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics. 2021;5(1):113–24.10.7150/ntno.51955 ↗
98. Zuo R, et al. Encapsulating halofuginone hydrobromide in TPGS polymeric micelles enhances efficacy against triple-negative breast cancer cells. Int J Nanomed. 2021;16:1587–600.10.2147/IJN.S289096 ↗
99. Zuo R, et al. Orally administered halofuginone-loaded tpgs polymeric micelles against triple-negative breast cancer: enhanced absorption and efficacy with reduced toxicity and metastasis. Int J Nanomed. 2022;17:2475–91.10.2147/IJN.S352538 ↗
100. Godugu C, et al. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). Colloids Surfaces B Biointerfaces. 2017;153:208–19.10.1016/j.colsurfb.2017.01.038 ↗